NEW YORK (Dow Jones)--Celgene Corp. (CELG) raised the price for its flagship blood cancer drug Revlimid by about 4.5% in the U.S. last week, bringing its cost to about $85,000 per year.
NEW YORK (Dow Jones)--Celgene Corp. (CELG) raised the price for its flagship blood cancer drug Revlimid by about 4.5% in the U.S. last week, bringing its cost to about $85,000 per year.
